Confirmed Fatal Colchicine Poisoning in an Adolescent with Blood and Bile Concentrations—Implications for GI Decontamination?

Trebach, Joshua; Boyd, Molly; Crane, Andrés; DiSalvo, Philip; Biary, Rana; Hoffman, Robert S.; Su, Mark

doi:10.1007/s13181-023-00946-2

Cited by 5 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colchicine is used for gout at a dose of 0.025 mg/kg/d clinically, and not all patients who take colchicine have liver damage. A case has been reported in which liver damage occurred when colchicine was administered in large doses (>0.5 mg/kg) [ 40 ]. In order to establish a colchicine-induced liver injury model, 3 mg/kg (bio-equivalent to 7.5 times the clinical dose) and 5 mg/kg (bio-equivalent to 12.5 times the clinical dose) doses of colchicine were used to induce liver injury based on body surface area.…”

Section: Methodsmentioning

confidence: 99%

Inhibition of CYP1A1 Alleviates Colchicine-Induced Hepatotoxicity

Huang,

Duan,

Huang

et al. 2024

Toxins

View full text Add to dashboard Cite

Colchicine, a natural compound extracted from Colchicum autumnale, is a phytotoxin, but interestingly, it also has multiple pharmacological activities. Clinically, colchicine is widely used for the treatment of gouty arthritis, familial Mediterranean fever, cardiovascular dysfunction and new coronary pneumonia. However, overdose intake of colchicine could cause lethal liver damage, which is a limitation of its application. Therefore, exploring the potential mechanism of colchicine-induced hepatotoxicity is meaningful. Interestingly, it was found that CYP1A1 played an important role in the hepatotoxicity of colchicine, while it might also participate in its metabolism. Inhibition of CYP1A1 could alleviate oxidative stress and pyroptosis in the liver upon colchicine treatment. By regulating CYP1A1 through the CASPASE-1-GSDMD pathway, colchicine-induced liver injury was effectively relieved in a mouse model. In summary, we concluded that CYP1A1 may be a potential target, and the inhibition of CYP1A1 alleviates colchicine-induced liver injury through pyroptosis regulated by the CASPASE-1-GSDMD pathway.

show abstract

Section: Methodsmentioning

confidence: 99%